A dose of AstraZeneca during a vaccination in Madrid, Spain.
-
Manu Fernandez / AP / SIPA
A reassuring new report?
No new case of atypical thrombosis (clots) associated with the AstraZeneca vaccine has been recorded, according to the latest report from the Medicines Agency, which specifies monitoring other "signals" as questions mount on side effects possible of this vaccine against Covid-19.
During the week of March 26 to April 1, "no new case of thrombosis of the large veins of atypical localization [...] was declared", indicated the ANSM on Friday in its weekly vaccine monitoring point.
While nearly 2.5 million doses of AstraZeneaca had been injected on April 1, the balance sheet is therefore still 12 cases, including 4 deaths linked to these thromboses since the start of the vaccination.
Skin problems and bleeding to watch out for
To date, no case of capillary leaks has been identified in France, adds the agency, in reference to a vascular problem characterized by the leakage of fluid from blood vessels and which is now also the subject of an investigation. of the European Medicines Agency (EMA).
On the other hand, the agency mentions two "signals" which will be "the subject of special surveillance".
"Two potential signals have been identified […] following cases of viral reactivation (shingles and herpes) as well as cases of bleeding, mainly from the nose, and hematomas," the press release said.
Due to the rare cases of thrombosis spotted in Europe and France, the High Authority for Health suspended the AstraZeneca vaccine in mid-March for those under 55 years of age.
For this category of people who have already received a dose of this vaccine, she recommended a second dose on Friday with Pfizer or Moderna.
Health
Vaccination: Delay on half of AstraZeneca deliveries to the European Union this week
Health
Vaccination: Olivier Véran plans to make messenger RNA vaccines "interchangeable"
Covid 19
Anti-covid vaccine
Coronavirus
Health
AstraZeneca
Vaccination